Aarti Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0LRU01027
  • NSEID: AARTIPHARM
  • BSEID: 543748
INR
989.80
-35 (-3.42%)
BSENSE

Nov 20

BSE+NSE Vol: 3.74 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Akums Drugs
Aarti Pharma
Blue Jet Health
Bliss GVS Pharma
Sanofi India
Strides Pharma
Viyash Scientifi
P & G Health Ltd
Sanofi Consumer
Concord Biotech
Symbiotec Pharma
Why is Aarti Pharmalabs Ltd ?
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.29 times
2
Positive results in Sep 26
  • NET SALES(Q) Highest at Rs 610.45 cr
  • PBT LESS OI(Q) At Rs 96.56 cr has Grown at 38.5% (vs previous 4Q average)
  • PAT(Q) At Rs 73.00 cr has Grown at 35.7% (vs previous 4Q average)
3
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 27-Oct-26 and has generated 11.85% returns since then
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST, DOW and OBV
4
With ROCE of 11.8, it has a Attractive valuation with a 3.1 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 38.86%, its profits have risen by 8.6% ; the PEG ratio of the company is 4
stock-recommendationReal-Time Research Report
Verdict Report
How much should you buy?
  1. Overall Portfolio exposure to Aarti Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Aarti Pharma for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Aarti Pharma
38.86%
0.81
48.25%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
5.23%
EBIT Growth (5y)
10.80%
EBIT to Interest (avg)
11.88
Debt to EBITDA (avg)
1.14
Net Debt to Equity (avg)
0.39
Sales to Capital Employed (avg)
0.85
Tax Ratio
24.63%
Dividend Payout Ratio
18.16%
Pledged Shares
11.98%
Institutional Holding
16.56%
ROCE (avg)
14.20%
ROE (avg)
11.85%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
34
Industry P/E
40
Price to Book Value
3.98
EV to EBIT
26.65
EV to EBITDA
20.22
EV to Capital Employed
3.15
EV to Sales
4.55
PEG Ratio
4.03
Dividend Yield
0.35%
ROCE (Latest)
11.81%
ROE (Latest)
11.55%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
Bullish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company
NET SALES(Q)

Highest at Rs 610.45 cr

PBT LESS OI(Q)

At Rs 96.56 cr has Grown at 38.5% (vs previous 4Q average

PAT(Q)

At Rs 73.00 cr has Grown at 35.7% (vs previous 4Q average

-7What is not working for the Company
INTEREST(9M)

At Rs 44.69 cr has Grown at 48.77%

DEBT-EQUITY RATIO(HY)

Highest at 0.40 times

Loading Valuation Snapshot...
Here's what is working for Aarti Pharma
Net Sales - Quarterly
Highest at Rs 610.45 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 610.45 cr has Grown at 24.0% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 492.26 Cr
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 96.56 cr has Grown at 38.5% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 69.73 Cr
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 73.00 cr has Grown at 35.7% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 53.82 Cr
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Here's what is not working for Aarti Pharma
Interest - Nine Monthly
At Rs 44.69 cr has Grown at 48.77%
over preceding nine months period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Debt-Equity Ratio - Half Yearly
Highest at 0.40 times
in the last five half yearly periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio